Wednesday, 22 November 2017
Latest news
Main » Analyst Ratings and Financial Health of Abbott Laboratories (NYSE:ABT)

Analyst Ratings and Financial Health of Abbott Laboratories (NYSE:ABT)

18 October 2017

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Nasdaq.com which released: "Abbott Labs posts quarterly profit vs. year-ago loss" on October 18, 2017, also Streetinsider.com with their article: "Abbott Laboratories (ABT) call put ratio 2.86 calls to 1 put into Q3" published on October 17, 2017, Barrons.com published: "Abbott Labs' Billion-Dollar Product" on September 29, 2017. Gilder Gagnon Howe & Co Llc sold 54,935 shares as Inphi Corporation Com Usd0.001 (IPHI)'s stock declined 24.15%. Finally, Segment Wealth Management LLC purchased a new position in shares of Abbott Laboratories in the second quarter worth $268,000.

A number of large investors have recently modified their holdings of ABT. Finally, Atwood & Palmer Inc. grew its position in Abbott Laboratories by 157.5% during the 1st quarter. Jacobs & Ca reported 1% of its portfolio in Abbott Laboratories (NYSE:ABT). Bank of New York Mellon Corp raised its holdings in Abbott Laboratories by 11.0% in the 1st quarter. Currently, 1.74 billion total shares are owned by the public and among those 1.72 billion shares have been available to trade. Coldstream Capital Management Inc. lifted its holdings in shares of Abbott Laboratories by 9.7% in the second quarter. The firm owned 129,206 shares of the healthcare product maker's stock after acquiring an additional 2,621 shares during the period.

Several equities analysts recently commented on ABT shares. Bailard, California-based fund reported 12,746 shares. The firm earned "Buy" rating on Thursday, July 14 by Jefferies. Guggenheim began coverage on shares of Abbott Laboratories in a research report on Thursday, June 29th. The stock of Everest Re Group Ltd (NYSE:RE) earned "Sell" rating by Keefe Bruyette & Woods on Thursday, August 17.

Shares of Abbott Laboratories (NYSE ABT) opened at 55.06 on Wednesday. Piper Jaffray downgraded Abbott Laboratories (NYSE:ABT) on Thursday, April 28 to "Neutral" rating. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock.

Heading into the stock price potential, Abbott Laboratories needs to grow just 1.59% to cross its median price target of $55.5.

Based on current stock levels, Abbott Laboratories shares are trading 0.85% off of the 50-day high and 16.34% away from the 50-day low. If you are reading this news story on another website, it was illegally stolen and republished in violation of USA and global copyright and trademark law.

Abbott Laboratories (ABT) is recuperating from the fall at $37.38, the 52-week low. The healthcare product maker reported $0.66 EPS for the quarter, beating the Zacks' consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. The average estimate of Wall Street analysts had projected 0.61. The Clearbridge Investments Llc holds 253 shares with $34,000 value, down from 11,532 last quarter.

The company said revenue for the quarter rose 28.9% to $6.83 billion. Fort Washington Invest Advsr Oh owns 228,792 shares for 0.18% of their portfolio.

Looking forward, the company's quarterly earnings are expected to come at $0.65 in the three months through September 2017 and $0.73 in the quarter ending December 2017, reflecting 10.17% and 12.31% growth, respectively. This represents a $1.06 annualized dividend and a yield of 1.93%.

In other news, insider Stephen R. Fussell sold 196,550 shares of the stock in a transaction that occurred on Wednesday, August 16th. Stock Yards Bank & Trust Co bought 15,698 shares as the company's stock declined 3.42% while stock markets rallied. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. $26,482 worth of Abbott Laboratories (NYSE:ABT) was sold by Watkin Jared on Thursday, June 15. The disclosure for this sale can be found here.

This particular stock's 5-day moving average is 54.70, its 20-day moving average is 53.78 and its 100-day moving average is 50.04. Cowen and Company reissued a "buy" rating and issued a $55.00 price target on shares of Abbott Laboratories in a report on Thursday, August 17th.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Ratings and Financial Health of Abbott Laboratories (NYSE:ABT)